Table 2.

Subgroup analysis for the HRs between high- and low-risk groups divided by the gene-pair signature

Subgroup	Number of patients		HR (95% CI)	Log-rank P-value
	High risk	Low risk
All	474	571	3.519 (2.870–4.314)	<0.0001
Age (years)
<65	172	217	3.856 (2.804–5.302)	<0.0001
≥65	228	335	4.349 (3.288–5.752)	<0.0001
Gender
Male	217	293	4.250 (3.198–5.648)	<0.0001
Female	183	260	3.984 (2.919–5.439)	<0.0001
Tumor location
Right	163	156	3.514 (2.519–4.903)	<0.0001
Left	186	246	3.796 (2.802–5.144)	<0.0001
TNM stage
I	17	65	0.289 (0.009–9.594)	0.4871
II	106	259	1.959 (1.156–3.322)	0.0125
III	112	203	2.579 (1.708–3.895)	<0.0001
IV	46	41	3.993 (2.032–7.845)	<0.0001
TP53 mutation
Yes	57	131	5.809 (3.387–9.962)	<0.0001
No	45	111	3.814 (1.960–7.422)	<0.0001
KRAS mutation
Yes	65	149	2.831 (1.666–4.811)	<0.0001
No	87	235	5.412 (3.265–8.968)	<0.0001
BRAF mutation
Yes	10	39	6.132 (1.339–28.09)	0.0205
No	129	325	3.837 (2.561–5.749)	<0.0001
Molecular subtype
C1	10	104	42.84 (9.319–196.9)	<0.0001
C2	13	88	0.499 (0.131–1.891)	0.3061
C3	10	61	4.728 (1.116–20.04)	0.0350
C4	42	17	2.622 (1.206–5.697)	0.0149
C5	57	95	4.078 (2.173–7.654)	<0.0001
C6	26	34	2.353 (1.055–5.247)	0.0365
Adjuvant chemotherapy
Yes	148	164	3.409 (2.423–4.796)	<0.0001
No	191	234	3.933 (2.892–5.347)	<0.0001